Heterogeneous tumors contain a few cancer cells (5-15%) and a multitude of other cells, such as immune cells and fibroblasts. They are difficult to treat because current diagnostic methods put all these cell types into a "blender" and then attempt to measure biomarkers in the resulting "smoothie."
2NA FISH aims to revolutionize cancer treatment decisions by developing the first spatial transcriptomics technology for clinical cancer diagnostics. By measuring up to 50 RNAs in a single-cell spatial context, we can provide more precise and predictive diagnostics for cancer treatment decisions.
